Press Releases

Date Title and Summary View
Toggle Summary Oxford Immunotec to Present at the Jefferies 2016 London Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Reports Third Quarter 2016 Financial Results
Third quarter revenue of $26.1 million, an increase of 46% compared to prior year period Tuberculosis revenue of $22.0 million, an increase of 23% compared to prior year period Tick-borne disease and other revenue of $4.1 million Completed acquisitions of Imugen and Immunetics expanding offerings
View HTML
Toggle Summary Oxford Immunotec Schedules Third Quarter 2016 Earnings Release and Conference Call for November 1, 2016
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated
View HTML
Toggle Summary Oxford Immunotec Acquires Immunetics, Inc.
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated
View HTML
Toggle Summary Oxford Immunotec Announces Closing of $40 Million in Debt Financing
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions,
View HTML
Toggle Summary Oxford Immunotec Announces Favorable Decision from U.S. District Court of Massachusetts in Patent Infringement Litigation
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions,
View HTML
Toggle Summary Oxford Immunotec Announces Favorable Recommendation by the Magistrate Judge in Patent Infringement Litigation
OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions,
View HTML
Toggle Summary Oxford Immunotec to Present at the Baird 2016 Global Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that
View HTML
Toggle Summary Oxford Immunotec Reports Second Quarter 2016 Financial Results
Second quarter revenue of $19.2 million, increased 34% compared to prior year period Raising revenue guidance for the full year from $79.5-$82.5 million to $82.5-$84.5 million Completed acquisition of Imugen, Inc. on July 1, 2016 for $22.2 million in all cash deal, accelerating entry into
View HTML
Toggle Summary Oxford Immunotec Schedules Second Quarter 2016 Earnings Release and Conference Call for August 2, 2016
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 18, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced
View HTML